AlzeCure Pharma AB (publ) announced that the Japenese Patent Office (JPO) has granted a patent covering the company's leading candidate drug ACD856, from the NeuroRestore platform, which is developed against Alzheimer's disease and other disorders with cognitive impairment. The company's patent application for ACD856 in Japan has been granted by the JPO. The patent number is 7350759 and the patent is expected to provide protection until 2039.

ACD856 and other substances in the NeuroRestore platform stimulate several important signaling systems and signaling molecules in the brain, such as BDNF (Brain Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), which can lead to improved cognition. The substance is under development as a symptom-relieving treatment for medical conditions where the cognitive ability is impaired, for example in Alzheimer's disease, and also for depression treatment. ACD856 has undergone phase I clinical studies, where both good safety and tolerability were demonstrated in humans, but also that the drug candidate crossed the blood-brain barrier and that the substance activated parts of the brain that are central to both cognition and depression treatment.

Previous preclinical studies have shown that AlzeCure's candidate drugs strengthen communication between nerve cells and improve cognitive ability, including learning and memory functions. New preclinical data also suggest that ACD856 has potential protective and disease-modifying effects.